Clinical Trial Update: Translational Neuroscience Optimization of GlyT1 Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a glycine transporter 1 (GlyT1) inhibitor for cognitive impairment in schizophrenia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• GlyT1 Inhibitor

Snippet

Sponsor: Yale University | Conditions: Cognitive Impairments Associated With Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2023-02-27